PhytoZon®
VINPOCETINE Benefits:
Benefits Coming Soon
VINPOCETINE Science:
Ingredient: VINPOCETINE - Works Cited:
(1) Brush J, Mendenhall E, Guggenheim A et al: The effect of Echinacea
purpurea, Astragalus membranaceus and Glycyrrhiza glabra on CD69
expression and immune cell activation in humans. Phytother Res. 2006
Aug;20(8):687-95. http://www.ncbi.nlm.nih.gov/pubmed/16807880.
(2) Jovanović ZB, Pavlović AM, Pekmezović T et al: Transcranial Doppler
assessment of cerebral vasomotor reactivity in evaluating the effects of
vinpocetine in cerebral small vessel disease: a pilot study. Ideggyogy Sz. 2013
Jul 30;66(7-8):263-8. http://www.ncbi.nlm.nih.gov/pubmed/23971358
(3) Skoromets AA, Aliev KT, Lalayan TV et al: Cognitive functions and
treatment of their impairment in elderly patients with the vertebrobasilar
insufficiency. Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(4):18-24.
(Russian). http://www.ncbi.nlm.nih.gov/pubmed/23739435
(4) Tabeeva GR, Azimova IuE: The multimodal strategy for the
neuroprotection in stroke: results of the Russian multicenter clinicalepidemiological
program SOKOL. Zh Nevrol Psikhiatr Im S S Korsakova.
2012;112(12 Pt 2):20-30. (Russian).
http://www.ncbi.nlm.nih.gov/pubmed/23388602
(5) Valikovics A, Csányi A, Németh L: Study of the effects of vinpocetin on
cognitive functions. Ideggyogy Sz. 2012 Mar 30;65(3-4):115-20. (Hungarian).
http://www.ncbi.nlm.nih.gov/pubmed/23136730
(6) Chukanova EI; Efficacy of cavinton in the treatment of patients with
chronic blood flow insufficiency. Russian multicenter clinical-epidemiological
program "CALIPSO". Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(12):49-
52. (Russian). http://www.ncbi.nlm.nih.gov/pubmed/21311488
(7) Gavrilova SI, Kolykhalov IV, Fedorova IaB et al: Possibilities of preventive
treatment of Alzheimer's disease: results of the 3-year open prospective
comparative study on efficacy and safety of the course therapy with
cerebrolysin and cavinton in elderly patients with the syndrome of mild
cognitive impairment. Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(1):62-9.
(Russian). http://www.ncbi.nlm.nih.gov/pubmed/20436440
(8) Afon'kin VIu, Dobretsov KG, Sipkin AV: The new scheme of cavinton
application to the treatment of chronic neurosensory loss of hearing. Vestn
Otorinolaringol. 2009; (6):69-70. (Russian).
http://www.ncbi.nlm.nih.gov/pubmed/20081798
(9) Skoromets AA, Tanashian MM, Chukanova EI et al: A multicenter program
on assessment of efficacy and safety of a new therapeutic scheme for
patients with chronic cerebrovascular insufficiency. Zh Nevrol Psikhiatr Im S S
Korsakova. 2009;109(5 Suppl 2):44-8. (Russian).
http://www.ncbi.nlm.nih.gov/pubmed/19894300
(10) Chukanova EI: Cavinton in the complex treatment of patients with
chronic cerebrovascular insufficiency. Zh Nevrol Psikhiatr Im S S Korsakova.
2009;109(9):35-9. (Russian). http://www.ncbi.nlm.nih.gov/pubmed/19770831
(11) Feher G, Koltai K, Kesmarky G et al: Effect of parenteral or oral
vinpocetine on the hemorheological parameters of patients with chronic
cerebrovascular diseases. Phytomedicine. 2009 Mar;16(2-3):111-7.
http://www.ncbi.nlm.nih.gov/pubmed/19135345
(12) Valikovics A: Investigation of the effect of vinpocetine on cerebral blood
flow and cognitive functions. Ideggyogy Sz. 2007 Jul 30;60(7-8):301-10.
(Hungarian). http://www.ncbi.nlm.nih.gov/pubmed/17713111
(13) Kemény V, Molnár S, Andrejkovics M et al: Acute and chronic effects of
vinpocetine on cerebral hemodynamics and neuropsychological
performance in multi-infarct patients. J Clin Pharmacol. 2005 Sep;45(9):1048-
54. http://www.ncbi.nlm.nih.gov/pubmed/16100299
(14) Szilágyi G, Nagy Z, Balkay L et al: Effects of vinpocetine on the
redistribution of cerebral blood flow and glucose metabolism in chronic
ischemic stroke patients: a PET study.J Neurol Sci. 2005 Mar 15;229-230:275-
84. http://www.ncbi.nlm.nih.gov/pubmed/15760651
(15) Vas A, Christer H, Sóvágó J et al: Human positron emission tomography
with oral 11C-vinpocetine]. Orv Hetil. 2003 Nov 16;144(46):2271-6.
(Hungarian). http://www.ncbi.nlm.nih.gov/pubmed/14702922
(16) Szapáry L, Horváth B, Alexy T et al: Effect of vinpocetin on the
hemorheologic parameters in patients with chronic cerebrovascular disease.
Orv Hetil. 2003 May 18;144(20):973-8. (Hungarian).
http://www.ncbi.nlm.nih.gov/pubmed/12830727
(17) Gulyás B, Halldin C, Sandell J et al: PET studies on the brain uptake and
regional distribution of [11C]vinpocetine in human subjects. Acta Neurol
Scand. 2002 Dec;106(6):325-32.
http://www.ncbi.nlm.nih.gov/pubmed/12460136
(18) Gulyás B, Halldin C, Sóvágó J et al: Drug distribution in man: a positron
emission tomography study after oral administration of the labelled
neuroprotective drug vinpocetine. Eur J Nucl Med Mol Imaging. 2002
Aug;29(8):1031-8. http://www.ncbi.nlm.nih.gov/pubmed/12173017
(19) Bönöczk P, Panczel G, Nagy Z: Vinpocetine increases cerebral blood flow
and oxygenation in stroke patients: a near infrared spectroscopy and
transcranial Doppler study. Eur J Ultrasound. 2002 Jun;15(1-2):85-91.
http://www.ncbi.nlm.nih.gov/pubmed/12044859
(20) Kolarov G, Orbetsova M, Nalbanski B et al: Complex effects of cavinton
on climacteric symptoms. Akush Ginekol (Sofiia). 2001;42(2):37-41.
(Bulgarian). http://www.ncbi.nlm.nih.gov/pubmed/11799757
(21) Feigin VL, Doronin BM, Popova TF et al: Vinpocetine treatment in acute
ischaemic stroke: a pilot single- blind randomized clinical trial. Eur J Neurol.
2001 Jan;8(1):81-5. http://www.ncbi.nlm.nih.gov/pubmed/11509086
(22) Truss MC, Stief CG, Uckert S et al: Initial clinical experience with the
selective phosphodiesterase-I isoenzyme inhibitor vinpocetine in the
treatment of urge incontinence and low compliance bladder. World J Urol.
2000 Dec;18(6):439-43. http://www.ncbi.nlm.nih.gov/pubmed/11204266
(23) Miyazaki M: The effect of a cerebral vasodilator, vinpocetine, on cerebral
vascular resistance evaluated by the Doppler ultrasonic technique in patients
with cerebrovascular diseases. Angiology. 1995 Jan;46(1):53-8.
http://www.ncbi.nlm.nih.gov/pubmed/7818157
(24) Hindmarch I, Fuchs HH, Erzigkeit H: Efficacy and tolerance of vinpocetine
in ambulant patients suffering from mild to moderate organic
psychosyndromes. Int Clin Psychopharmacol. 1991 Spring;6(1):31-43.
http://www.ncbi.nlm.nih.gov/pubmed/2071888
(25) Dutov AA, Gal'tvanitsa GA, Volkova VA et al: Cavinton in the prevention of
the convulsive syndrome in children after birth injury. Zh Nevropatol
Psikhiatr Im S S Korsakova. 1991;91(8):21-2. (Russian).
http://www.ncbi.nlm.nih.gov/pubmed/1661506
(26) Kiss E: Adjuvant effect of cavinton in the treatment of climacteric
symptoms. Ther Hung. 1990;38(4):170-3.
http://www.ncbi.nlm.nih.gov/pubmed/2094056
(27) Bhatti JZ, Hindmarch I: Vinpocetine effects on cognitive impairments
produced by flunitrazepam. Int Clin Psychopharmacol. 1987 Oct;2(4):325-31.
http://www.ncbi.nlm.nih.gov/pubmed/3693872
(28) Balestreri R, Fontana L, Astengo F: A double-blind placebo controlled
evaluation of the safety and efficacy of vinpocetine in the treatment of
patients with chronic vascular senile cerebral dysfunction.J Am Geriatr Soc.
1987 May;35(5):425-30. http://www.ncbi.nlm.nih.gov/pubmed/3553281
(29) Pilgramm M, Schumann K: Need for rheologically active, vasoactive and
metabolically active substances in the initial treatment of acute acoustic
trauma. HNO. 1986 Oct;34(10):424-8. (German).
http://www.ncbi.nlm.nih.gov/pubmed/2432041
(30) Domzał T, Kozłowski P, Zaleska : Cavinton in the treatment of ischemic
cerebral stroke. Clinical and computerized-tomographic evaluation. Neurol
Neurochir Pol. 1986 May-Jun;20(3):234-40. (Polish).
http://www.ncbi.nlm.nih.gov/pubmed/3537828
(31) Subhan Z, Hindmarch I: Psychopharmacological effects of vinpocetine in
normal healthy volunteers. Eur J Clin Pharmacol. 1985;28(5):567-71.
http://www.ncbi.nlm.nih.gov/pubmed/3899677
(32) Bodo D, Kotovskaia AR, Galle RR et al: Effectiveness of the preparation
Gavinton in preventing motion sickness. Kosm Biol Aviakosm Med. 1982 May-
Jun;16(3):49-51. (Russian). http://www.ncbi.nlm.nih.gov/pubmed/7098411
SMG, Inc., American Dream Nutrition, LLC. 2018 All rights reserved. No income claims or guarantees are made or implied. Individual results and incomes are determined by each person's efforts to build and promote their business. *These statements have not been evaluated by the Food and Drug Administration. These products and information are not intended to diagnose, treat, cure or prevent disease. Take as directed and always consult with your doctor or healthcare professional before taking any supplements.